PHILADELPHIA (May 15, 2017) – Medical oncologists Lori Goldstein, MD, and Elias Obeid, MD, MPH, are opening a phase 2 immunotherapy clinical trial for newly diagnosed, locally recurrent, or metastatic HER2-overexpressing breast cancer.

PHILADELPHIA (January 9, 2017) – Martin J. Edelman, MD, a nationally renowned expert in the research and treatment of lung cancer, has joined Fox Chase Cancer Center as Chair of the Department of Hematology/Oncology and as deputy cancer center director for clinical research. He will start on February 6, 2017.

PHILADELPHIA (May 25, 2016) — In a study of those patients with advanced non-squamous non-small cell lung cancer (NSCLC), those treated with the drug OPDIVO^® (nivolumab) demonstrated improved overall survival over patients treated with the drug Taxotere^® (docetaxel). 

PHILADELPHIA (April 5, 2016) —  "Our findings have broad implications for the design of future clinical trials and the interpretation of current and previous studies,” said lead study investigator Nicholas G. Zaorsky, MD, resident physician in radiation oncology at Fox Chase.

In addition to excellent clinical care, Fox Chase Cancer Center is home to a team of world-renowned cancer researchers who develop and test therapies not available anywhere else. For more than a century, Fox Chase has been a key contributor in advancing understanding of cancer prevention,...

As a National Cancer Institute (NCI)-designated Comprehensive Cancer Center, Fox Chase Cancer Center offers our patients the most advanced treatment options through clinical trials, many of which are not readily available elsewhere. Our nationally ranked doctors specialize in the development of these studies — specifically phase 1 and 2 trials.

Immunotherapy has emerged over the past several years as a promising avenue in cancer medicine. Researchers at Fox Chase Cancer Center are in the midst of a Phase 1 clinical trial with support from Horizon Pharma to investigate ways to boost the efficacy of immune checkpoint drugs, seeking better outcomes for more patients.

As a National Cancer Institute (NCI)-designated Comprehensive Cancer Center, Fox Chase Cancer Center offers our patients the most advanced treatment options through clinical trials, many of which are not readily available elsewhere. Our nationally ranked doctors specialize in the development of these studies — specifically phase 1 and 2 trials.  A pilot clinical trial about stage 2-4 HIV-associated Hodgkin Lymphoma will be led by Stefan Barta, MD, a medical oncologist at Fox Chase who specializes in Hematology.